1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Care Facilities
Apollo Hospitals Enterprise Limited

Apollo Hospitals Enterprise Limited

APOLLOHOSP.BO
Apollo Hospitals Enterprise LimitedIN flagBombay Stock Exchange
8,834.00
INR
-58.30
- -
1.27TMarket Cap
Apollo Hospitals Enterprise Limited
APOLLOHOSP.BO
(Bombay Stock Exchange)

Recent

price

8,834.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
210.24
241.51
273.41
315.13
372.22
446.7
519.79
591.07
689.59
801.19
747.75
1,010.97
1,143.71
1,311.84
1,515.74
1,754.57
1,464.21
Revenue per Share
14.17
16.29
21.45
22.02
23.76
16.99
15.88
8.44
16.96
32.7
10.74
73.42
56.97
62.5
100.56
135.04
102.17
Basic EPS, GAAP
-6.03
-0.57
-15.78
-17.14
-28.62
-30.1
-3.66
-6.07
16.27
56.06
69.23
72.25
17.28
54.48
29.47
62.15
- -
Free Cash Flow per Basic Share
3.49
3.59
4.04
5.5
5.75
11.61
- -
7.25
6.02
11.15
2.74
3.01
17.75
15
19
20
- -
Dividend per Share
5.03
10.64
13.77
18.83
29.98
17.36
29.96
23.7
31.63
35.64
47.5
121.14
148.21
197.83
279.11
5
- -
Book Value per Share
142.28
180.55
187.56
202
224.71
219.7
215.18
210.7
217.05
220.59
310.11
337.67
378.31
429.28
510.01
605.26
- -
Tangible Book Value per Share
124
130
138
139
139
139
139
139
139
139
140
144
144
144
144
144
154
Basic Weighted Avg Shares
26,054
31,475
37,687
43,842
51,785
62,147
72,316
82,233
95,939
111,466
104,680
145,362
164,448
188,623
217,940
252,285
225,505
Sales/Revenue/Turnover
14.76
12.92
12.81
12
10.67
7.31
6.05
5.51
7.03
9.28
5.42
10.93
8.81
9.05
10.39
11.47
10.66
Operating Margin (%)
942
1,236
1,420
1,671
2,117
2,659
3,140
3,590
3,955
6,197
5,731
6,007
6,154
6,870
7,575
8,761
7,948
Depreciation Expense
1,755
2,122
2,957
3,063
3,306
2,364
2,210
1,174
2,360
4,549
1,504
10,556
8,191
8,986
14,459
19,417
15,735
Net Income, GAAP
33.41
35.27
26.32
25.02
28.55
29.17
40.96
65.27
46.54
34.12
38.38
30.23
22.4
32.27
26.19
24.74
25.6
Effective Tax Rate (%)
6.74
6.74
7.85
6.99
6.38
3.8
3.06
1.43
2.46
4.08
1.44
7.26
4.98
4.76
6.63
7.7
6.98
Profit Margin (%)
2,462
3,360
8,192
7,041
9,432
7,247
11,659
6,529
3,263
3,096
16,035
16,263
10,121
6,152
24,500
4,185
- -
Working Capital
7,480
5,744
10,789
12,224
18,577
24,498
29,534
29,238
29,521
47,196
37,036
37,605
34,359
42,170
43,858
51,004
- -
LT Debt
19,238
25,194
27,641
29,955
33,517
34,091
34,378
33,839
34,690
34,697
48,024
59,030
65,313
73,205
86,529
99,745
- -
Total Equity
9.47
8.54
9.71
9.47
8.1
5.55
4.08
2.39
5.26
8.54
3.93
11.93
10.99
10
12.72
13.48
- -
Return on Invested Capital (%)
21.53
25.54
29.75
24.93
19.03
12.26
13.07
7.02
10.41
14.92
7.35
22.19
16.1
14.84
18.72
23.44
35.74
Return on Capital (%)
199.25
211.13
180
135.59
97.36
71.79
67.15
31.46
61.32
97.21
25.91
87.72
42.3
36.12
42.17
95.06
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
10,334
- -
LT Borrowings
- -
19,719
- -
LT Finance Leases
- -
24,139
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
144
- -
Market Capitalization
1,048,836
1,019,860
1,115,464

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
70,289
- -
Cash, Cash Equivalents & STI
- -
20,104
- -
Accounts Receivable, Net
- -
30,161
- -
Inventories
- -
4,808
- -
Total Current Liabilities
- -
45,789
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
10,334
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.93%
15.82%
15.27%
Free Cash Flow
9.04%
42.3%
110.93%
Net Income, GAAP
75.78%
136.87%
34.29%
Sales/Revenue/Turnover
15.48%
19.6%
15.76%
Total Cash Common Dividend
- -
103.78%
5.27%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
44,178
48,469
48,506
47,470
188,623
2025
50,856
55,893
55,269
55,922
217,940
2026
58,421
64,774
66,055
- -
252,285

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11.59
16.2
17.06
- -
62.5
2025
21.23
26.34
25.89
21.1
100.56
2026
30.1
34.94
36.82
- -
135.04

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
15
2025
- -
- -
- -
- -
19
2026
- -
- -
- -
- -
20
Similar Companies
Dr. Soliman Abdul Kader Fakeeh Hospital Co. (4017.SR)
Gian Life Care Limited (GIANLIFE.BO)
China Evergrande New Energy Vehicle Group Limited (0708.HK)
Jack Nathan Medical Corp. (JNHMF)
dentalcorp Holdings Ltd. (DNTL.TO)
Soni Medicare Limited (SML.BO)
Business
Apollo Hospitals Enterprise Limited operates as one of India's largest integrated healthcare providers, offering a comprehensive range of medical services including multi-specialty hospitals, primary care clinics, diagnostic centers, pharmacies, and telemedicine platforms. The company delivers specialized treatments across cardiology, oncology, neurology, orthopedics, gastroenterology, and organ transplants; operates under brands such as Apollo Hospitals, Apollo Cradle, Apollo Spectra, and Apollo 24/7 for digital health; and provides preventive health checks, laboratory services, and medical education through Apollo Hospitals Educational and Research Foundation. Founded in 1983 and headquartered in Chennai, India, it manages over 70 hospitals, 5,000 pharmacy outlets, and primary clinics primarily in India, with select operations in Bangladesh, Nigeria, and Mauritius, serving patients through a network focused on urban and semi-urban markets. In recent developments, Apollo Hospitals Enterprise Limited expanded its digital health footprint with the growth of Apollo 24/7, launching new features for online consultations and home healthcare services in 2024. The company formed strategic partnerships, including collaborations with international firms for advanced robotic surgery systems and AI-driven diagnostics announced in mid-2025. Additionally, it completed the acquisition of certain assets from Keystone Realtors in 2024 to bolster real estate for healthcare infrastructure and raised funds through qualified institutional placements exceeding INR 10 billion in late 2024 to support expansion into tier-2 cities and new specialty centers.